Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 86 of 121 for:    prostate cancer AND prostate cancer screening | ( Map: United States )

177Lu−J591 and 177Lu−PSMA−617 Combination for mCRPC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03545165
Recruitment Status : Recruiting
First Posted : June 4, 2018
Last Update Posted : July 30, 2019
Sponsor:
Information provided by (Responsible Party):
Weill Medical College of Cornell University

Brief Summary:
Phase I dose escalation study with combination of 177Lu−J591 and 177Lu−PSMA−617 using a dose-fractionated regimen will be performed in patients with documented progressive metastatic CRPC. The cumulative 177Lu−J591 dose for each subject will be 2.7 GBq/m2 (73 mCi/m2) of 177Lu with 20 mg J591 and the cumulative 177Lu−PSMA−617 dose for each subject will vary (depending on the Cohort) from 3.7 GBq (100 mCi) to 18.5 GBq (500 mCi). The 177Lu−PSMA−617 dose will be escalated in up to 6 different dose levels (3+3 dose−escalation study / de-escalation design). For the phase II portion, a minimum number of 14 patients will be enrolled at MTD (including those enrolled at MTD in Phase I) and a maximum of 24.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: 177Lu−PSMA−617 Drug: 177Lu−J591 Drug: 68Ga−PSMA−HBED−CC Phase 1 Phase 2

Detailed Description:

This is an open−label, single−center Phase I dose−escalation study designed to determine the dose−limiting toxicity (DLT) and the maximum tolerated dose (MTD) of combination of 177Lu−J591 and 177Lu−PSMA−617 in a two−week dose−fractionation regimen. 177Lu−J591 will be given at a moderate dose previously demonstrated to be safe x2 infusions two weeks apart. For 177Lu−PSMA−617 the dose escalation will start at 3.7 GBq (100 mCi) and escalate in increments of 1.85 GBq (50 mCi) for each dose to a planned maximum of 9.25 GBq (250 mCi) x2 doses, 2 weeks apart. Should there be unacceptable toxicity at the initial dose level, we will de-escalate to dose level -1 (1.85 GBq / 50 mCi per dose). After the phase I study has established a MTD, the Phase II, single-arm trial will start.

Patients must have documented progressive metastatic CRPC disease based on Prostate Cancer Working Group 3 (PCWG3) criteria in order to be eligible for enrollment. Upon meeting the inclusion and exclusion criteria and signing the informed consent and HIPPA form, subjects will undergo the screening. As part of the screening, subjects will get a single dose of 68Ga−PSMA−HBED−CC and will have a PET/CT. Nuclear Medicine physician(s) will review the PET/CT scans to document PSMA expression at tumor site(s).

Subjects will have Lutetium−177 Planar/SPECT Imaging on Day 8 (±1 day) after the first dose of 177Lu−J591 + 177Lu−PSMA−617. Optimal images will be performed on selected consenting subjects between the initial treatment visit #1 on Day 1 and Day 4 and prior to treatment visit #2 on D15 ±1. Subjects will be closely monitored for AEs (weekly x2 weeks, then every 2 weeks for one month, at 8 and 12 weeks, and then every 4 weeks for next 3 months).

Upon completion of investigational treatment with dose−fractionation regimen of the combination of 177Lu−J591 + 177Lu−PSMA−617, subjects will undergo 68Ga−PSMA−HBED−CC injection and same day PET/CT at the end of study visit to document treatment response. Subsequently survival data and additional treatment(s) information will be captured from their routine Standard of care (SOC) visits.

.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Dose−Escalation Trial of Combination Fractionated-dose 177Lu−J591 and 177Lu−PSMA−617 in Patients With Metastatic Castration−Resistant Prostate Cancer
Actual Study Start Date : April 18, 2018
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : June 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: All Subjects

177Lu−PSMA−617 [1.85 GBq (50 mCi) - 9.25 GBq (250 mCi)] x2 doses, 2 weeks apart (Treatment Visit #1 and #2), IV administration

177Lu−J591 [1.35 GBq/m2 or 36.5 mCi/m2] x2 doses, 2 weeks apart (Treatment Visit #1 and #2), IV administration

68Ga−PSMA−HBED−CC [185 ±74 MBq or 5 ±2 mCi] intravenous during screening and at 12 weeks (±1 week) with standard imaging

Drug: 177Lu−PSMA−617
[1.85 GBq (50 mCi) - 9.25 GBq (250 mCi)]

Drug: 177Lu−J591
[1.35 GBq/m2 or 36.5 mCi/m2]

Drug: 68Ga−PSMA−HBED−CC
[185 ±74MBq or 5 ±2 mCi]




Primary Outcome Measures :
  1. Dose limiting toxicity (DLT) of combination therapy in a 2−week dose−fractionation regimen [ Time Frame: Approximately 3 months after enrollment ]
  2. Cumulative maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of combination therapy in a 2−week dose−fractionation regimen [ Time Frame: Approximately 3 months after enrollment ]
  3. The proportion with PSA decline following the dose−fractionated combination therapy by comparing the change in PSA levels after therapy to the baseline, pre−treatment PSA. [ Time Frame: At baseline and at 2 weeks on therapy ]

Secondary Outcome Measures :
  1. Radiographic response rate by RECIST 1.1 with PCWG3 modifications [ Time Frame: At the efficacy (scan) visit time point (12 weeks) ]
  2. Biomedical progression−free survival by PCWG3 criteria [ Time Frame: At the efficacy (scan) visit time point (12 weeks) ]
  3. Radiographic progression−free survival by PCWG3 criteria [ Time Frame: At the efficacy (scan) visit time point (12 weeks) ]
  4. Overall survival following treatment with the combination of 177Lu−J591 and 177Lu−PSMA−617 in a 2−week dose−fractionation regimen [ Time Frame: Approximately 3 months after enrollment until study completion, approximately 36 months, or death ]
  5. Safety of treatment with the combination of 177Lu−J591 and 177Lu−PSMA−617 in a 2−week dose−fractionation regimen as assessed by CTCAE 4.0 [ Time Frame: Up to 6 months after first treatment ]
  6. Changes in CTC count as measured by CellSearch [ Time Frame: At the efficacy (scan) visit time point (12 weeks) ]
  7. Rate of favorable CTC count as measured by Cell Search [ Time Frame: At the efficacy (scan) visit time point (12 weeks) ]
  8. Rate of favorable LDH count [ Time Frame: During treatment phase, then every 4 weeks until radiographic progression, assessed up to 6 months ]
  9. Patient reported outcomes using FACT−P [ Time Frame: During treatment phase, then every 12 weeks until radiographic progression, assessed up to 6 months ]
  10. Patient reported outcome using the Brief Pain Inventory short form [ Time Frame: During treatment phase, then every 12 weeks until radiographic progression, assessed up to 6 months ]

Other Outcome Measures:
  1. Disease assessment with PSMA−ligand based imaging prior to and following investigational treatment [ Time Frame: Up to 12 weeks ]
  2. Immune effects of PSMA−targeted radionuclide therapy [ Time Frame: Up to 12 weeks ]
  3. Genomic DNA repair pathways in relationship to outcome following treatment with the combination of 177Lu−J591 and 177Lu−PSMA−617 in a 2−week dose−fractionation regimen [ Time Frame: Up to 12 weeks ]
  4. Whole body distribution of combination therapy [ Time Frame: Up to 12 weeks ]
  5. Radiation dosimetry of combination therapy [ Time Frame: Up to 12 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Subjects who have documented progressive metastatic CRPC disease, who meet the inclusion and exclusion criteria will be eligible for participation in this study.
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Histologically or cytologically confirmed adenocarcinoma of prostate
  2. Documented progressive metastatic CRPC based on Prostate Cancer Working Group 3 (PCWG3) criteria, which includes at least one of the following criteria:

    i. PSA progression ii. Objective radiographic progression in soft tissue iii. New bone lesions

  3. ECOG performance status of 0−2
  4. Have serum testosterone < 50 ng/dL. Subjects must continue primary androgen deprivation with an LHRH/GnRH analogue (agonist/antagonist) if they have not undergone bilateral orchiectomy.
  5. Have previously been treated with at least one of the following:

    • Androgen receptor signaling inhibitor (such as enzalutamide)
    • CYP 17 inhibitor (such as abiraterone acetate)
  6. Have previously received taxane chemotherapy, been determined to be ineligible for taxane chemotherapy by their physician, or refused taxane chemotherapy.
  7. Age > 18 years
  8. Patients must have normal organ and marrow function as defined below:

    • Absolute neutrophil count >2,000 cells/mm3
    • Hemoglobin ≥9 g/dL
    • Platelet count >150,000 x 109/L
    • Serum creatinine <1.5 x upper limit of normal (ULN) or calculated creatinine clearance ≥ 60 mL/min/1.73 m2 by Cockcroft−Gault
    • Serum total bilirubin<1.5 x ULN (unless due to Gilbert's syndrome in which case direct bilirubin must be normal)
    • Serum AST and ALT<1.5 x ULN in the absence of liver metastases; <3 x ULN if due to liver metastases (in both circumstances bilirubin must meet entry criteria)
  9. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

  1. Implantation of investigational medical device ≤4 weeks of Treatment visit #1 (Day 1) or current enrollment in oncologic investigational drug or device study
  2. Use of investigational drugs ≤4 weeks or <5 half−lives of Treatment visit # 1(Day 1) or current enrollment in investigational oncology drug or device study
  3. Prior systemic beta−emitting bone−seeking radioisotopes
  4. Known active brain metastases or leptomeningeal disease
  5. History of deep vein thrombosis and/or pulmonary embolus within 1 month of Treatment visit #1
  6. Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or hematological organ systems which might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study
  7. Radiation therapy for treatment of PC ≤4 weeks of Treatment visit #1
  8. Patients on stable dose of bisphosphonates or denosumab, which have been started no less than 4 weeks prior to treatment start, may continue on this medication, however patients are not allowed to initiate bisphosphonate/Denosumab therapy during the DLT−assessment period of the study.
  9. Having partners of childbearing potential and not willing to use a method of birth control deemed acceptable by the principle investigator and chairperson during the study and for 1 month after last study drug administration
  10. Currently active other malignancy other than non−melanoma skin cancer. Patients are considered not to have "currently active" malignancy if they have completed any necessary therapy and are considered by their physician to be at less than 30% risk of relapse.
  11. Known history of known myelodysplastic syndrome

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03545165


Contacts
Layout table for location contacts
Contact: GUONC Research Team 212-746-7851 guonc@med.cornell.edu

Locations
Layout table for location information
United States, New York
Weill Cornell Medical College Recruiting
New York, New York, United States, 10021
Contact: GUONC Research Team       guonc@med.cornell.edu   
Sponsors and Collaborators
Weill Medical College of Cornell University
Investigators
Layout table for investigator information
Principal Investigator: Scott Tagawa, MD Weill Cornell Medicine

Layout table for additonal information
Responsible Party: Weill Medical College of Cornell University
ClinicalTrials.gov Identifier: NCT03545165     History of Changes
Other Study ID Numbers: 1802018988
First Posted: June 4, 2018    Key Record Dates
Last Update Posted: July 30, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases